Compare Amgen, Inc. (AMGN) vs iShares Bitcoin Trust (IBIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs iShares Bitcoin Trust — how do they compare? Amgen, Inc. trades at $356.83 (market cap $196.12B), while iShares Bitcoin Trust trades at $35.55. The key difference: Amgen, Inc. pays a 2.77% dividend while iShares Bitcoin Trust pays none, and Amgen, Inc. is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals.
| AMGN | IBIT | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Crypto-linked |
52-Week High | $388.16 | $71.29 |
52-Week Low | $271.18 | $33.29 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
IBIT trades at $36.23, up 1.17% today, with neutral technical signals from moving averages and oscillators. Support and resistance cluster around $35-$36. The stock's financial ratios are unavailable, but recent news highlights its position as a leading spot Bitcoin ETF with $44.9 billion in assets under management as of June 2026, per The Motley Fool.
Outlook remains tied to Bitcoin ETF flows and investor sentiment toward crypto-linked equities. Risks include market volatility and competitive pressure from other ETFs. Institutional interest is strong, but performance depends heavily on broader cryptocurrency trends and regulatory developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →
